Question special
Lead Moderator

The authors began recruiting patients into the TAILORx study approximately 10 years ago.

Now, in the field of breast cancer prognosis in 2015, have there been further valuable prognostic genes discovered which may warrant inclusion in an assay? In other words, should the 21-gene assay evolve into a more-than-21-gene assay to potentially give patients and clinicians more prognostic and/or treatment guidance?